TScan Therapeutics

NASDAQ: TCRX ↗$0.79 USD~$120M (mid-2026) MCAP

#TCR-T Cell Therapy #Allogeneic Hematopoietic Cell Transplantation #Hematologic Malignancies #Solid Tumor Immunotherapy #Cell Therapy Manufacturing

TScan Therapeutics is a clinical-stage immunotherapy company developing a portfolio of TCR-T cell therapies for hematologic malignancies and solid tumors. The company's lead program TSC-101 is in the ALLOHA Phase 1 study for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, with positive initial data from Cohort C reported in 2026 showing 11 of 14 dosed patients achieving complete donor chimerism. TScan is preparing TSC-101 for a planned Phase 3 study in blood cancers as the next value-driving event. The company has also established a Cellares automated-manufacturing agreement for TSC-101 production scalability. TScan is headquartered in Waltham, Massachusetts and trades on the Nasdaq Capital Market under the symbol TCRX.

Company Info

Sector:Biotechnology / Cell Therapy (TCR-T Engineered T Cells)

Headquarters:Waltham, Massachusetts, USA

Founded:2018

Website:www.tscan.com/

Upcoming Milestones & Key Dates

Late Q3 2026

Clinical Data

Next data cut from the ALLOHA Phase 1 study of TSC-101

Q2 2026

Corporate

Q2 2026 financial results and pipeline update

Clinical Development Pipeline

TSC-101

Target: TCR-T cell therapy directed against minor histocompatibility antigens (HA-1, HA-2)

Hematologic malignancies (post-allogeneic HCT relapse prevention); planned Phase 3 in blood cancers

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Solid tumor TCR-T pipeline

Target: TCR-T cell therapy platform

Multiple solid tumor indications (undisclosed targets)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gavin MacBeath, Ph.D.

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Waltham, MA

Apply Now →